TRIAL DETAIL

A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients

Drug:
Trial Name:
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Recruiting
Phase:
2
Start Date 10/01/2011
Age of Trial (yrs) 8
Treatment Phase:
Gleevec-resistant
Drug Category:
HSP90 inhibitor
Strategy:
Destroy KIT
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
T2211
Sponsor:
National Health Research Institutes, Taiwan
Patient Contact:
Brong-rong Chen, BS 886-2-2653-4401 ext 25162 brong@nhri.org.tw
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
Eight hospitals in Taiwan are participating.

National Health Research Institutes, Taiwan
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan
Mackay Memorial Hospital
Taichung Veterans General Hospital
China Medical University Hospital
National Cheng-Kung University Hospital
Chang Gung Memorial Hospital

Trial Links

Trial Results

Drug Information

LRG Story about the discovery of Hsp90 inhibitors for GIST.
 
Full text article - NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models - Jensen -2008
 
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells
 
Full text article - NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
 
AACR 2012 - HSP90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression
 

Trial Sites

Name
Address
City
State
Zip
Country
Taiwan